Stent-assisted reconstructive endovascular repair of intracranial aneurysms: long-term clinical and angiographic follow-up by VANNUCCI, STEFANO
1 
 
Stent-Assisted Reconstructive Endovascular 
Repair of  
Intracranial Aneurysms  
Long-Term Clinical and Angiographic Follow-Up 
 
Index 
 
Abstract                                                                                                pag. 3 
               
CHAPTER 1: “INTRACRANIAL ANEURYSM AND ITS 
TREATMENT”. 
  
1.1 Introduction                                                  pag. 5 
1.2 Cerebrovascular anatomy and pathophysiology of aneurysms pag. 6  
1.3 Risk of aneurysm rupture                                                             pag. 7  
1.4 Treatment options                                                                          pag. 8 
1.4.1 Surgical clipping                                                                          pag. 8 
1.4.2 Endovascular coiling                                                                   pag. 9 
1.4.3 Stent-asisted coiling                                                                     pag. 12 
1.4.4 Flow diversion                                                                              pag. 16 
1.5 Comparison of surgical clipping and coil embolization              pag. 17 
 
CAPITOLO 2: “CLINICAL STUDY”. 
2.1 Material and methods                                          pag. 21 
2.2 Results                                  pag. 24 
2 
 
2.3 Discussion                             pag. 27 
2.4 Conclusion                                                                                 pag. 31 
 
References                                     pag. 32 
Pictures                              pag.41  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
Abstract 
 
Background and Purpose: The development of self-expanding stents dedicated to 
intracranial use has significantly widened the applicability of endovascular therapy to 
many intracranial aneurysms. The purpose of this study was to report the 
angiographic and clinical outcomes of wide-necked intracranial aneurysms treated 
with stent.Methods: Between January 2007 and October 2011 we deployed 22 stents 
in 20 patients with wide-necked cerebral aneurysms. Inclusion criteria restricted the 
group to adult patients with wide-necked intracranial aneurysms (ruptured and 
unruptured lesions). Immediate post-procedural angiographic studies were performed 
to evaluate successful occlusion of the aneurysm as well as patency of the parent 
vessel. We assessed long term angiography follow-up to detect in-stent stenosis, 
progressive thrombosis, recurrence and need for retreatment. Clinical outcome was 
assessed with the modifing Ranking Scale (mRS). Results: Technical success was 
obtained in all 22 (100%) cases. Angiography immediately after treatment procedure 
showed complete occlusion in  7 aneurysms (35%), neck remnant in 11 (55%), 
incomplete occlusion in 1 (5%) and partial occlusion in 1 (5%). During the 
endovascular embolization procedure no rupture of the sac or bleeding complication 
occurred; none of the patients needed undergoing surgical crossover. Procedure-
related adverse events occurred in one (5%) patient: a brachial artery 
pseudoaneurysm. Three (15%) patients had neurological complications after 
procedure, whose 1 (5%) transitory complication spontaneusly resolved. Two patients 
(10%), had acute complete in-stent thrombosis which resolved after intraarterial 
administration of abciximab and placement of a new stent in-stent. Of the 20 patients 
treated with stent deployment, a follow-up imaging study was available in all 19 
surviving patients (95%) at an average of 16.2 months (range, 6 to 50 months). The 
first follow-up DSA, compared with initial angiography, showed no changes in 14 
aneurysms (73.7%), progressive thrombosis in 3 (15.7%), and major recurrence in 2 
(10.5%). The overall rate of succesful procedure to 6 months is 89.5%; there was 1 
case of asintomatic moderate endothelial hyperplasia. The further follow-up imaging 
study, showed no changes in 17 (89.5%) of the 19 surviving patients, 1 progressive 
thrombosis and 1 minor recurrence. One month- and long term (average of 16.2 
months; range, 6 to 50 months) clinical follow-up showed no worsening in the mRS 
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in 18 (90%) of 20 patients, 1 (5%) mRS 2 and 1 (5%) mRS 6.All the survived patients 
are alive and we did not observe periprocedural or long-term intracranial bleeding 
events or symptomatic stent related stenosis/occlusion complication. 
Conclusions: Our findings suggest that the endovascular treatment of intracranial 
aneurysms by stenting is feasible, effective and safe; follow-up results proved intact 
parent arteries and stable occlusion rates in the majority of treated aneurysms. 
Nevertheless, long-term data on safety and efficacy and larger patient groups are 
necessary. 
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CHAPTER 1: “INTRACRANIAL ANEURYSM AND ITS 
TREATMENT”. 
 
 
1.1 INTRODUCTION  
 
Subarachnoid hemorrhage (SAH) is the most serious presentation of ruptured 
intracranial aneurysms. Autopsy reports have shown that aneurysms are present in 
roughly 5% of the population, yet most are often asymptomatic (1). Estimated annual 
incidence rates of SAH range from 10 to 15 cases per 100,000, which translates to at 
least 30,000 annual cases of SAH in the United States. Two-thirds of patients with 
aneurysm rupture either die or have a disabling neurological deﬁcit (2). In recent 
years, an increasing number of unruptured, incidental aneurysms are being detected 
due to increased availability of non-invasive imaging modalities. While it is clear that 
most ruptured aneurysms must be treated to prevent rerupture, the management of the 
unruptured intracranial aneurysms (UIA) is more complex both from treatment 
decision making perspectives. Aneurysms typically develop during adulthood and 
rupture risk increases with age. The mean age for aneurysmal SAH is about 50 years 
(3). Typical locations at risk for the development of aneurysms are branching points, 
where structural irregularities in the collagen matrix exist (4), and elevated 
hemodynamic stresses due to segments involving short radii of curvature are more 
observed. Studies have shown that abnormal hemodynamic stress plays an important 
role in aneurysm formation and growth (5).  
Intracranial aneurysms can be classiﬁed using several schemes. The most obvious 
division is considering the ruptured and unruptured lesions separately. With respect to 
morphology, aneurysms are classiﬁed as saccular or non-saccular. Non-saccular 
intracranial aneurysms such as fusiform, dolichoectatic, and dissecting aneurysms are 
rare with an incidence of less than 0.1% (6). Another system of classiﬁcation is by 
aneurysm location. The predominant location for saccular aneurysms is the anterior 
circulation (90%), with most arising from the circle of Willis. The anterior 
communicating complex (30–35%) is the most common location, followed by the 
internal carotid artery (30%). The basilar apex represents the most common location 
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in the posterior circulation and accounts for 10% of all intracranial aneurysms (7). 
Aneurysms are also classiﬁed by size into subgroups of small (< 10 mm), large (10–
25 mm), and giant (> 25 mm) in diameter. According to Wiebers et al. (8), aneurysms 
smaller than 12 mm in dome size account for more than 75% of the unruptured 
aneurysms. The establishment of endovascular therapy has led to further classiﬁcation 
of aneurysms based on the size of the neck. Management of UIA remains a topic of 
debate due to incomplete and often conﬂicting data relating to the natural history of 
aneurysms, along with the risks associated with treatment (9).  
While published studies may present different aneurysm rupture risk levels, they all 
indicate that treatment is recommended due to the poor outcome of rupture. Ruptured 
aneurysms account for approximately 85% of non-traumatic SAH and are associated 
with a 30-day mortality rate of 45% and a morbidity rate of 25% (10). In a study of 
hospital discharge records for patients with ruptured and unruptured aneurysms, 
mortality rates for SAH demonstrated little change with the introduction of 
endovascular treatments (11). In addition to poor outcomes and co-morbidities 
resulting from SAH, economic burden associated with SAH must also be taken into 
consideration. Dodel et al. (12) recently published a study on the cost of illness due to 
SAH, the total accumulated costs in the ﬁrst year were € 38,300 (95% CI, € 34,490 to 
€ 43,100). Their data also indicate higher costs associated with younger patients. The 
method of treatment for ruptured intracranial aneurysms, however, remains a problem 
with no clear solution.  
 
1.2 CEREBROVASCULAR ANATOMY AND PATHOPHYSIOLOGY OF 
ANEURYSMS 
 
 It is suggested that formation of an intracranial aneurysm is a consequence of a 
systemic vascular pathology, which is associated with pleomorphism in different 
candidate genes (13). A higher prevalence of aneurysms in the cerebrovascular 
system may also be due to alterations in hemodynamic and histological characteristics 
(4, 14). Cerebral arteries are particularly susceptible to aneurysm formation due to the 
absence of an external elastic lamina, paucity of supportive perivascular tissues, 
attenuated tunica media, and irregularities near bifurcations (4). The internal elastic 
lamina is an important layer of the arterial wall especially in the cerebral vessels. 
Thus, disruption of this layer would promote formation of aneurysms (15). 
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Particularly, the regions around the bifurcations have atypical wall structures with a 
discontinuity of the muscle cells of the tunica media as a medial defect in connection 
with a predominance of collagen ﬁbers over the elastic ones (4). In addition to this 
speciﬁc structure, non-uniform collagen framework in the bifurcation region of brain 
arteries might further induce development of intracranial aneurysms (4). 
Swietaszczyk et al. (16) demonstrated that arterial blood ﬂow disturbance and 
hypertension in the brain vessels lead to increased hemodynamic stress on arterial 
walls. Some studies also present strong association between wall shear stress (WSS) 
and initiation of cerebral aneurysm formation in experimental models (14). A 
prolonged high WSS induces matrix metalloproteinase production and fragmentation 
of the internal elastic lamina at, or immediately adjacent to the bifurcation (5, 14). 
Prolonged elevation of blood pressure leads to excessive mechanical loading and 
causes remodeling of the arterial wall. The exact mechanisms involved in this tissue 
remodeling are not completely understood, but the decreased structural integrity of 
the tissue may be one of the underlying reasons of aneurysm formation and growth.  
 
1.3 RISK OF ANEURYSM RUPTURE 
  
The International study of unruptured intracranial aneurysms (ISUIA) has been the 
most comprehensive clinical study of its kind to date (17). The study enrolled 4,060 
patients from the US, Canada, and Europe. In phase II of ISUIA trial, there were a 
total of 6,221 unruptured aneurysms among different studied cohorts (i.e., operated 
and unoperated) (8). A higher rupture rate was reported to be associated with larger 
aneurysms, location in the posterior circulation, and previous history of SAH. The 5-
year cumulative rupture rate, for patients with no history of SAH and aneurysm size 
between 7 and 12 mm, was 2.6 and 14.5% for aneurysms located in the anterior and 
posterior circulation, respectively. The greatest risk of rupture, for large size 
aneurysms in the posterior circulation, was 50% (8). Juvela et al. (18) followed 142 
patients with 181 aneurysms for a total of 2,575 person years and reported a rupture 
rate of 1.46% per year (95% CI: 1.04–2.04). Rinkel et al. (19) presented data on nine 
studies, totaling 3,907 patient years and similarly concluded a rupture rate of 1.9% 
(95% CI: 1.5–2.4). Prevalence of aneurysms and rupture risks were shown to increase 
in both studies due to the factors such as size of the unruptured aneurysm, age of the 
patient, pre-existing familial conditions, and hypertension. Smoking has been also 
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associated with higher prevalence of aneurysms and rate of rupture (18). More recent 
studies have begun to focus on additional quantiﬁcation methods of aneurysms to 
predict rupture risks. Several geometric indices, measured by using three-dimensional 
rotational angiography or digital subtraction angiography, have correlated to 
increased rupture rates. Ryu et al. (20) compared geometric indicators of 109 
unruptured and 105 ruptured aneurysms to develop imaging predictor markers of 
aneurysm rupture. The two highest indicators were the aspect ratio (the ratio of the 
aneurysm’s height to its neck) and the volume to neck ratio. From the published data 
in the literature, larger aneurysms have an increased risk of rupture. Raghavan et al. 
(21) noted that two other factors, the undulation index and the non-sphericity index, 
are strong predictors of aneurysm rupture as well.  
 
1.4 TREATMENT OPTIONS  
 
1.4.1 SURGICAL CLIPPING  
 
The ﬁrst direct operation on an intracranial aneurysm was performed by Norman Dott 
in 1931 (22). In 1937, Walter Dandy performed the ﬁrst operation for clipping an 
intracranial aneurysm, in which he applied a silver clip across the neck of a posterior 
communicating artery aneurysm (23). Introduction of operative microscopes, 
development of dedicated aneurysm clips and of advanced surgical approaches were 
instrumental to improving outcomes from aneurysm surgery. Factors such as site, 
size, and age-speciﬁc risks of repair for each patient should be considered in the 
treatment of UIA (8).  
A detailed description of open surgical technique for aneurysm clipping is beyond the 
scope of this study. Some important steps include patient positioning, planning of the 
craniotomy, and a microsurgical approach to clipping of the aneurysm. Depending on 
the location of the aneurysm, speciﬁc arachnoidal dissection is necessary to obtain 
proximal control of the parent artery. Once this is achieved, the aneurysm can be 
exposed and dissected under high magniﬁcation. The middle cerebral artery (MCA) 
bifurcation aneurysms serve as examples of the various approaches available.  
There are three different approaches to expose the MCA aneurysm in the sylvian 
ﬁssure. The sylvian ﬁssure can be opened from medial (proximal) to lateral (distal) or 
vice versa. The lateral to medial approach requires less brain retraction and is usually 
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more direct to these superﬁcial aneurysms (24). Alternatively, an incision in the 
superior temporal gyrus with subpial resection can be used to expose the aneurysm 
(25). This approach may be particularly useful when there is an associated temporal 
lobe hematoma. Thereafter, routinely the parent artery is prepared for temporary 
clipping before deployment of the permanent clips (26). Temporary clipping of the 
parent artery is useful in the event of an intraoperative aneurysm rupture. Moreover, it 
is useful to reduce the turgor of the aneurysm and facilitate permanent clip application 
across the aneurysm neck. However, there may be a higher risk of ischemic 
complications with temporary clipping (27). Prior to temporary clipping, blood 
pressure may be elevated pharmacologically and cerebral protectants such as 
barbiturates, propofol, or etomidate can be administered to reduce the risk of 
ischemia. Finally, after placement of the permanent clip on the aneurysmal neck, 
intraoperative micro-Doppler, non-invasive near infrared indocyanine green 
videoangiography, or invasive intraoperative cerebral angiography are employed to 
assess the patency of the parent artery as well as the entire occlusion of the aneurysm 
neck (28).  
 
1.4.2 ENDOVASCULAR COILING 
  
In 1939, the ﬁrst endovascular treatment of an intracranial aneurysm was performed, 
in which 30 feet of silver wire were placed into a giant cavernous carotid aneurysm 
that had eroded the orbit (29). Luessenhop and Velasquez (30) ﬁrst described 
catheterization of the intracranial arteries and catheter based embolization of an 
intracranial aneurysm. In the early 1970s, Serbinenko (31), considered by many to be 
the founder of endovascular neurosurgery, developed a series of balloon mounted 
ﬂow guided catheters and detachable balloons designed to occlude intracranial 
vascular lesions. In the 1980s and early 1990s, Guglielmi et al. (32, 33) combined the 
concepts of electrothrombosis and endovascular approaches to develop a detachable 
coil system. Guglielmi detachable coils (GDC) were approved by the Food and Drug 
Administration (FDA) and form the basis of contemporary endovascular treatment of 
intracranial aneurysms. Endovascular therapy for aneurysms is attractive because an 
effective and often equivalent result can be achieved with a less invasive method 
compared to traditional microsurgery. This may result in decreased hospitalization 
and faster recovery times for the patient (34).  
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The following is an overview of the key steps of the coil embolization procedure. It 
can be performed under general anesthesia or conscious sedation depending on the 
patient’s ability to cooperate, the complexity of the aneurysm, and the operator’s 
preference. Aneurysm coiling is typically performed using biplane ﬂuoroscopic 
guidance. A typical procedure involves gaining access to the common femoral artery 
and navigating a guide catheter, ranging from 5 to 7 French in diameter, into the 
internal carotid artery or vertebral artery. A microcatheter, ranging in size from 1.7 to 
2.3 French, is then advanced over a microwire (typically 0.014′′ ). Once the best 
projection of the aneurysm is obtained (i.e., a view that clearly delineates the 
aneurysm neck and surrounding arterial branches), the microcatheter is advanced into 
the aneurysm. Platinum coils of various conﬁgurations and sizes are deployed and 
detached through the microcatheter. The coils are detached using either a hydraulic or 
electrolytic mechanism. 
In general terms, the ﬁrst coil is either sized or slightly undersized to the maximum 
diameter of the aneurysm. For example, a 7-mm coil would be a reasonable ﬁrst coil 
for a 7.3-mm diameter aneurysm. After framing coils are placed, the subsequent coils 
are two-dimensional “ﬁlling” or “ﬁnishing” coils. Additional coils are deployed until 
the aneurysm is no longer ﬁlling with contrast or until additional coils cannot be 
placed safely. The latter condition is often represented by either the ﬁnal coil or the 
microcatheter protruding into the parent artery.  
There are a variety of microcatheters, microwires, and coils available in the market. 
The choice of device depends on the vascular tortuosity, the navigability and stability 
of the catheter, and ultimately operator preference.  
The early experience with coiling tended to be limited to aneurysms with narrow 
necks. Wide necked aneurysms, deﬁned from an endovascular standpoint as those 
with a dome-to-neck ratio > 2 or an absolute neck diameter > 4 mm, were not 
amenable to coil embolization until technological advancements in the late 1990s and 
early 2000s. Three major advancements have expanded the indications for coil 
embolization of these wide-neck aneurysms. First, the introduction of three-
dimensional coils has allowed for complex framing conﬁgurations to be achieved with 
less coil protrusion into the parent artery. Second, the development of balloon assisted 
coil embolization has allowed for improved packing density of coils and also reduces 
the risk of coil protrusion into the parent vessel. In this technique, a compliant balloon 
is navigated and inﬂated across the neck of an aneurysm as coils are introduced into 
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the aneurysm through the microcatheter. The balloon can also arrest ﬂow in the parent 
artery in the event of an intraprocedural aneurysm rupture. Finally, stent-assisted coil 
embolization has allowed for treatment of the very wide necked aneurysms and 
diffusely diseased segments of arteries. The microcatheter can be navigated through 
the pores of the stent into the aneurysm or can be trapped between the artery wall and 
the stent. In addition to improving coil packing density and preventing coil protrusion, 
the stent may divert ﬂow away from the aneurysm and allow vessel remodeling. 
Currently several stents are available, including Enterprise stent system (Codman, 
J&J, Raynham, MA, USA), Neuroform stent system (Stryker, Kalamazoo, MI, USA) 
and Leo stent system (Balt, Montmorency, France).  
Murayama et al. (35) described a single center experience with GDCs during an 11-
year period from 1990–2002. A total of 916 aneurysms in 818 patients were treated 
by coiling and results were separated into patients treated before and after FDA 
approval of coils. This study included patients with acute SAH (49%), unruptured 
aneurysms (42%), and non-acute SAH (9%). Three hundred thirty-four aneurysms 
(36.5%) were small, 198 (21.6%) were large, 73 (8%) were giant. The overall results 
were complete occlusion in 504 (55%) of 916 aneurysms, and a neck remnant was 
seen in 234 (35.4%). Complete occlusion was highest (86.2%) in small diameter and 
small neck aneurysms, the occlusion rate was reduced by approximately half in the 
other groups which subsquenlty had increases in the amount of neck remants.  
Another study by Gonzalez et al. (36) examined 247 UIA treated at the UCLA 
Medical Center during a similar time period (1991–2000). Of those UIA’s, 118 
(54.4%) were found incidentially during angiography, CT angiography, or MR 
angiograghy, and 51 (23.5%) presented with mass effect. Angiographic results 
indicating complete occlusion were achieved in 138 (55%) of 247 aneurysms, 
incomplete occlusion in 3 (1.2%), and neck remnants in 92 (37.2%).  
Further evaluation of the results, stratiﬁed into the aneurysm size groups described in 
the Murayama et al. (35) study, show higher  success rates for complete occlusion in 
smaller aneurysms. Of the 83 small aneurysms with narrow necks, 63 (75%) were 
completely occluded, while 20 (23.8%) had a neck remnamt. As aneurysm size 
increased, the likeliness of complete occlusion was greatly reduced, with success 
being achieved in 7 (24.1%) of 29 giant aneurysms. Wanke et al. (37) published 
endovascular treatment results of 39 patients harboring 42 unruptured aneurysms. The 
study included 18 small (0–5 mm), 11 medium (6–10 mm), 9 large (11–25 mm), and 
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4 giant (> 25 mm) aneurysms. Endovascular treatment was deemed technically 
feasbible in 38 aneurysms, with 4 being unable to be treated due to an unfavorable 
dome-to-neck ratio. They reported complete (100%) or near complete (95–99%) 
occlusion in 34 (89.5%) aneurysms. Incomplete occlusion (< 95%) was achieved in 
four aneurysms (three large and one giant).  
While endovascular coiling of intracranial aneurysms has offered an alternative 
treatment option to open surgery, there are serious risks to consider. Some of these 
risks overlap with those seen in open surgery and others are unique to endovascular 
therapy. Murayama et al. (35) reported procedural complications in 69 (8.45%) 
patients, the most common being thromboembolism in 24 (2.4%) patients. This 
percentage is also similar to the cerebral embolization reported by Gonzalez et al.  
(3.7%) (36). Other complications include aneurysm perforation, parent artery 
occlusion, coil migration, arterial dissection, and vasospasm. A major shortcoming of 
aneurysm coiling, especially in the early era of the therapy, was durability. The main 
etiology for recanalization is coil compaction. Another mechanism may be 
rearrangement of individual coil loops. Insufﬁcient packing of the aneurysm neck 
increases the chances of aneurysm recurrence (38). The ability to increase packing 
density has improved with the introduction of three-dimensional coils and hydrogel 
coated coils that swell when exposed to blood. The clinical relevance of aneurysm 
recanalization for endovascluar approach is not settled unless rerupture risks for 
coiled aneurysms and surgical clipping are comparable. Clinical outcomes of 
aneurysm coiling are superior for small to medium size aneurysms when compared to 
giant and fusiform aneurysms. (A review of 46 studies encompassing 8,161 coiled 
aneurysms showed a 91% rate of adequate occlusion at initial treatment (39). 
Recanalization was reported in 21% of aneurysms, and retreatment was performed in 
10%. ). 
At our institution, we typically perform at least one follow-up angiogram in the first 6 
months. The results of the follow-up angiogram determine the need for additional 
angiograms. We have also found magnetic resonance angiography (MRA) to be an 
useful alternative in detecting recanalization in majority of  cases.  
 
1.4.3 STENT-ASSISTED COILING 
  
Stents have been developed as an endovascular approach to open blocked arteries in 
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patients for reestablishing normal blood ﬂow to tissue at risk. The ﬁrst coronary stent 
was implanted in a human in 1986, and by 1999 its use had increased to 83% of all 
endovascular interventions in the coronary arteries (40). The early stents were made 
of stainless steel and were deployed using a balloon catheter to mechanically force 
open the vessel to increase blood ﬂow. The evolution of coronary stents eventually 
led to self- expanding stents, eliminating the need for balloon angioplasty to expand 
the stent against the arterial wall. Material advances also led to the development of 
stents comprised of super-elastic metals. The combination of these two technologies 
enabled stents to be extremely ﬂexible and expand without the use of rigid balloon 
catheters, which in turn reduces the tendency of vessel rupture due to arterial wall 
damage during deployment. These improvements, in conjunction with the 
introduction of microcatheters and microwires, enabled clinicians to navigate and 
deliver stents to previously inaccessible areas, more speciﬁcally the cerebral 
vasculature. The ﬁrst stent designed for treatment of aneurysms was the Neuroform 
stent, which received a Humanitarian Device Exemption from the FDA in late 2002 
(41). The primary objective of a stent application is to provide a scaffold for coiling 
an aneurysm with difﬁcult shapes and sizes with a wide neck.  
Fiorella et al. (41) were among the earliest to report results from stent-assisted coiling 
immediately following the FDA limited approval use of the device for broad-neck, 
fusiform, or giant aneurysms. The study included a total of 74 aneurysms in 64 
patients, however only 61 aneurysms were treated with stent-assisted coiling. Follow-
up angiographic (average 4.6 months) results were available for 48 aneurysms. Eleven 
patients showed an increase in residual aneurysm size, seven of which underwent 
additional coil embolization. Residual aneurysm decreased or resolved in 25 patients, 
while no change was observed in 12 patients. Similar results were shown by Lubicz et 
al. (42), who treated 15 unruptured aneurysms in 14 patients with stent-assisted 
coiling. All patients showed excellent (neurologically intact) clinical outcome after 
the procedure. Lubicz et al. (43) published another study, utilizing the Leo stent (Balt, 
Montmorency, France) and Enterprise stent (Codman, J&J, Raynham, MA, USA), on 
long term follow up of patients treated with stent-assisted coiling. Thirty-four 
aneurysms, all wide-neck (neck > 4 mm or neck/sac ratio > 0.7), were treated in 32 
patients. Follow up was performed at 6 months (n = 4 patients), 12 months (n = 16 
patients), and 36 months (n = 12 patients) with a mean of 20 months. Final 
angiographic results (performed between 6 and 36 months) showed that aneurysm 
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occlusion was complete in 27 (79%), neck remnant in 3 (9%), and incomplete in 4 
(12%).  
Favorable results were also shown by Weber et al. (44) for the treatment of 31 wide-
neck saccular aneurysms in 30 patients. Successful stent placement with adequate coil 
positioning, without any procedural complications, was achieved in 28 (90%) of 31 
aneurysms. At 6 months, they observed complete occlusion in 15 (50%) aneurysms, 
neck remnants in 8 (26.7%) aneurysms, and 7 (23.3%) residual aneurysms. Results 
also revealed that 29 (93.5%) of the parent arteries were unaffected, while 2 parent 
vessels had minor asymptomatic narrowing at the stent site.  
Vendrell et al. (45) assessed stent-assisted coiling in 49 patients presenting a total of 
52 unruptured MCA aneurysms. Fifty (96.2%) aneurysms were successfully treated; 
two were referred to surgery after catheterization of the parent vessel was 
unsuccessful. At a follow-up period of 14 ± 9 months, complete treatment was 
observed in 34 (71%) aneurysms, residual necks were present in 6 (12%), and 
incomplete occlusion in 8 (17%).  
Biondi et al. (46) reported retrospective results of stent-assisted coiling in the 
treatment of 46 wide-neck aneurysms in 42 patients, however only 40 aneurysms 
were successfully treated with stents and coils. Follow-up results of 30 aneurysms 
treated by stent-assisted coiling showed 17 (57%) aneurysm occlusions, 7 (23%) 
presented neck remnants, and 6 (20%) had a residual aneurysm.  
A recent study published by Piotin et al. (47) presented results on the endovascular 
repair of 1,325 aneurysms using coils, including 216 that were treated by stent-
assisted coiling. One hundred eighty-one (83.8%) of the aneurysms receiving a stent 
were unruptured. The analysis of angiographic follow up showed that stented 
aneurysms hade lower recurrence rates vs. non-stented aneurysms. The study showed  
that the use of stents was beneﬁcial in terms of angiographic stability in both ruptured 
(P = 0.0339) and unruptured (P = 0.0073) aneurysms.  
The analysis of treatment by endovascular approach of non-ruptured aneurysms 
(ATENA), published by Pierot et al. (48), has been one of the most comprehensive 
studies on the treatment of unruptured aneurysms. The study included 649 patients, 
harboring 739 aneurysms. Seven hundred twenty-seven aneurysms were treated using 
coils (98.4%). Coils alone were used in 396 aneurysms (54.4%), with balloon 
remodeling in 271 cases (37.3%), intracranial stents in 57 cases (7.8%), and the 
Trispan neck bridge in 3 cases (0.4%). Treated aneurysms were divided into four size 
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categories: 131 (17.7%) aneurysms were 1–3 mm, 304 (41.1%) aneurysms were 4–6 
mm, 215 (29.1%) aneurysms were 7–10 mm, and 89 (12.0%) aneurysms were 11–15 
mm. Fusiform and dissecting aneurysms were excluded from the study, as well as 
patients who had experienced a SAH from another aneurysm within the last month. 
Initial results indicated postoperative complete occlusion in 436 aneurysms (59.0%); 
neck remnant in 160 aneurysms (21.7%), and aneurysm remnant in 143 aneurysms 
(19.3%). Another study by Pierot et al. (49) further broke down the analysis of the 
ATENA results for each treatment technique. The ATENA study shows that the 
viability of endovascular treatment of unruptured aneurysms can be achieved in large 
number of cases (95.7%) with low mortality and morbidity (1.4 and 1.7%, 
respectively).  
Stent-assisted coiling has improved the ability to treat difﬁcult and complicated 
aneurysms since its FDA approval in 2002. New clinical techniques continue to 
emerge along with advances in-stent design. However, while these devices provide 
another treatment option for endovascular repair, additional risks are associated with 
stent placement compared to coiling alone. Placing a stent in the parent artery requires 
lifetime use of anti-platelet agents to reduce the risk of thrombosis based stenosis 
within the stent. Kanaan et al. (50) reported acute in-stent thrombosis or chronic 
stenosis in 9 of 133 stent-coil deployments (6.8%) during a mean follow up of 15.4 
months. The need for anti-platelet therapy limits the role of stent placement in 
patients with ruptured aneurysms. These patients may need additional invasive 
procedures such as ventriculostomy, decompressive craniectomy, tracheostomy, or 
gastrostomy. The risk of these procedures is increased due to anti-platelet or 
anticoagulation therapy. Mocco et al. (51) showed a high rate of mortality in patients 
with SAH when compared to the unruptured cohort (12 vs. 0.8%, respectively). In the 
study reported by Piotin et al. (47), mortality rates were similarly high (6.0 vs. 1.2% 
in aneurysms treated with stent and without stent, respectively). Differences in 
procedural complications were also statistically signiﬁcant (P = 0.027) when 
comparing results of aneurysms treated with stent (7.4%) and those treated without a 
stent (3.8%). The increase in complications translated into higher procedure related 
deaths (4.6 to 1.2%, P = 0.006). Long term studies are needed to further evaluate in-
stent thrombosis or stenosis. Due to their high porosity, stents surface area coverage 
of aneurysm neck is relatively low (4 to 7%). Therefore while they may provide 
improved stability for coiling, they are not sufﬁcient as a stand-alone therapy of the 
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majority of intracranial aneurysms.  
 
1.4.4 FLOW DIVERSION  
 
With advent of computational ﬂuid dynamics over the past few decades, more and 
more research has begun focusing on advancing aneurysm treatment options. 
Improvement in imaging modalities has greatly inﬂuenced medical device design. The 
latest neuroendovascular devices for treating intracranial aneurysms to reach the 
market are ﬂow diverters. So far, limited clinical approval has been achieved on any 
such device, but procedures are performed under FDA exemption for compassionate 
use (52). The primary goal of a ﬂow diversion device is to divert ﬂow away from the 
aneurysm by placing a mesh structure, similar to a stent, on the aneurysm neck along 
the parent artery. By decoupling blood ﬂow between the parent artery and aneurysmal 
sack, a ﬂow diverter can create blood stasis to allow for thrombus formation inside the 
aneurysm. Flow diverters are intended to be used in anatomical situations where stent-
assisted coiling becomes difﬁcult, such as giant or fusiform aneurysms. In terms of 
design, they are very similar to stents, consisting of a highly ﬂexible tubular structure 
with a mesh. They differ in one major aspect, the porosity of the cells or mesh is less 
than typical stents. Therefore, the major focus in manufacturing design for ﬂow 
diverters has been shift from radial force exerted by the stent on the vessel wall to 
ﬂow alternation inside the aneurysm (from solid mechanics to ﬂuid mechanics). These 
scaffolds, or constructs, are speciﬁcally designed for use in the neurovasculature, 
where as stent design evolved from its original coronary application. Many studies are 
available on flow-diversion (53, 54, 55, 43, 56). 
Current research continues to materialize on the use of ﬂow diverters to treat 
intracranial aneurysms. These devices are typically deployed in situations where 
established techniques, such as coiling and stent-assisted coiling, are not viable 
options. It is not surprising that with increased technical demands, comes increased 
technical complications with deployment of ﬂow diverters. Lubicz et al. (43) reported 
an overall complication rate of 38%, including parent artery stenosis, distal embolism, 
in-device thrombosis, branch occlusion, and hemorrhage or mass effects. They also 
reported parent artery stenosis in eight cases (33%) at follow up. In another study, 
parent artery occlusion was seen in seven (14%) patients, with additional arterial 
narrowing in three (6%) patients (56).  
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Stents used for coil stability do not substantially reduce blood ﬂow to the aneurysm 
sack as compared to ﬂow diverters. Clinicians must use caution in deployment of ﬂow 
diverters when aneurysms are located near regions of side branching arteries. 
Incorrect placement could prevent blood ﬂow to an otherwise healthy artery. Another 
concern with ﬂow diverters is the low porosity, needed to reduce blood ﬂow, will be 
problematic if additional coiling is needed after deployment due to the small open 
spaces in the mesh. Anti-coagulants required for ﬂow diverters may be beneﬁcial for 
prevention of in-device thrombus, but could negatively impact the time for thrombus 
formation inside the aneurysm without the additional coil packing used with stents.  
The interaction of thrombus formation inside aneurysms is not clearly understood and 
has been suggested it could lead to rupture after deployment of a ﬂow diverter (55). 
The mechanisms behind this phenomenon could relate to a reduction in WSS below 
normal physiological values (57), leading to vessel remodeling and rupture. 
Endovascular treatment of intracranial aneurysms using ﬂow diverters is a relatively 
novel approach, with a small number of clinical results available, and more 
information is needed to fully evaluate the effectiveness. It should be noted that 
Pipeline Embolization Device (PED), owned by Covidien, Mansﬁeld, MA, USA 
(previously owned by eV3, Inc./Chestnut Medical Technologies, Inc., Menlo Park, 
CA, USA) and SILK (eV3, Inc./Chestnut Medical Technologies, Inc., Menlo Park, 
CA, USA) has recently been approved by the FDA Neurological Devices Advisory 
Panel as ﬂow diversion device for treatment of aneurysms, and is currently awaiting a 
ﬁnal decision by the FDA committee.  
 
1.5 COMPARISON OF SURGICAL CLIPPING AND COIL EMBOLIZATION  
 
The advent of endovascular therapy has certainly reduced the role of open surgery. 
For some aneurysms, endovascular treatment is preferred, whereas for others surgery 
is still superior in both cost and outcomes (23). The choice of open surgery vs. 
endovascular surgery for aneurysms, whether ruptured or unruptured, remains an 
individualized decision. The following factors play a role in treatment decision 
making:  
1) age, past medical history, and medical/neurological conditions help to determine 
the patient’s ability to tolerate a speciﬁc treatment. For example, a patient with a 
ruptured aneurysm in poor neurological condition likely has a diffusely swollen, 
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friable brain, and coil embolization may be superior to surgery in this setting. On the 
other hand, a young patient with an unruptured aneurysm may be a good candidate for 
open surgery in anticipation of achieving a durable result. In some instances, patient 
preference also plays a role in which treatment is chosen.  
2) Aneurysm characteristics such as location (suitability for surgical access), 
morphology, and size. Basilar apex aneurysms are associated with higher surgical 
morbidity compared to other locations, so endovascular treatment is usually the 
preferred choice of treatment. On the other hand, MCA aneurysms tend to have 
complex morphologies with wide necks and important arterial branches may be 
incorporated into the aneurysm. These aneurysms tend to be more suitable for open 
surgery. A ruptured aneurysm with a large intracerebral hematoma and mass effect 
may be better suited for surgery.  
3) Finally, operator preferences are often understated but equally important. This 
includes the operator’s bias toward a certain treatment because of experience and 
familiarity. Some complex aneurysms may require a combination of open and 
endovascular surgeries.  
The International subarachnoid aneurysms trial (ISAT) was a randomized, multicenter 
study that compared clinical outcomes of patients presenting with ruptured 
aneurysms, and treated either by clipping or by coiling (17). A total of 9,559 patients 
with SAH were assessed, and 2,143 patients were ultimately enrolled and 
randomized. Initial clinical outcomes from ISAT indicated little difference between 
endovascular and surgical treatment. However, the results at 1 year follow up were 
convincing enough to lead to an early termination of the study, because those treated 
with endovascular coiling had a 6.9% absolute risk reduction and 22% relative risk 
reduction in poor outcome compared with surgical clipping (17). Long term follow-
ups in ISAT indicated endovascular coiling had a higher risk of re-bleeding than 
clipping, but the risk was low and remained similar to risk of SAH from another 
aneurysm (58).  
The ISAT study indicated that endovascular treatment was a safe and effective 
alternative to surgical treatment for certain ruptured aneurysms. However, the results 
were not sufﬁcient to determine that endovascular treatment is superior to surgical 
treatment in all patients with ruptured aneurysms and cannot be applied to unruptured 
aneurysms. The trial demonstrated that coil embolization resulted in less peri-
procedural morbidity in a selected group of patients. Retreatment was performed in 
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17.4% of the 1,096 patients who underwent endovascular therapy and in 3.8% of the 
1,012 patients who underwent surgical clipping (59).  
A recent study reported by Alshekhlee et al. (60) compared hospital mortality and 
complication rates associated with aneurysm clipping and coiling based on the 
National Inpatient Sample (NIS) between 2000 and 2006. A total of 3,738 patients 
had aneurysm clipping and 3,498 had endovascular coiling. For clipping vs. 
endovascular coiling, both median length of hospital stay (4 and 1 days, respectively, 
P < 0.0001) and mortality (1.6 vs. 0.57%, respectively) were higher. The study also 
presented data showing a trend in hospital use of endovascular coiling has increased 
during recent years.  
Singh et al. (61) showed that increased clinician experience with endovascular coiling 
resulted in decreased risk of complications. The combination of these factors may be 
advantageous for endovascular treatment, but similar comparative studies have to be 
conducted.  
 
In conclusion, licterature data confirm: 
advances in imaging modalities and knowledge of natural history and prevalence of 
aneurysms have increased detection of unruptured asymptomatic intracranial 
aneurysms. An unbiased assessment of most appropriate course of treatment is crucial 
for achieving a favorable outcome;  
the size of an aneurysm has been associated with higher risk of complications for both 
surgical and endovascular treatment approach (62). Studies reporting on the risk of 
rupture and outcomes have provided much insight but the debate remains of how and 
when unruptured aneurysms should be managed; 
the studies reviewed here support the generalized notion that endovascular treatment 
of UIA provides a safe and effective alternative to surgical treatment. The risks 
associated with endovascular repair are lower and incur shorter hospital stays for 
appropriately selected patients; 
the method of endovascular treatment should be considered based on factors such as 
aneurysm size, location, patient medical history, and clinician experience. To date, 
there have been no randomized large studies comparing outcomes using different 
endovascular options. The likeliness of such a study appears slim as the variability in 
the use of devices is wide. Furthermore, the rapid development of endovascular 
technology often prevents adequate appraisal of existing devices and methods. 
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Currently, endovascular therapy and surgical therapy must be viewed as 
complementary rather than competitive in the treatment of intracranial aneurysms. 
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CHAPTER 2: “CLINICAL STUDY”. 
 
2.1 MATERIALS AND METHODS 
 
Between January 2007 and October 2011, we deployed 22 stents in 20 patients 
harboring wide-necked cerebral aneurysms. Inclusion criteria restricted the group to 
adult patients (>18 years old) with wide-necked intracranial aneurysms (ruptured and 
unruptured lesions) and follow-up imaging studies (DSA or MRA) perormed at our 
Institution. A wide neck was defined as a dome-neck ratio of less than 2 or a neck that 
was 4 mm or wider as measured on angiograms.  
The study consisted of 18 (90%) women and 2 (10%) men with a mean age of 56.2 
years (range 37-83 years). Eleven (55%) aneurysms were located in the anterior 
circulation and nine (45%) in the vertebrobasilar system.  
According to the ISUIA II (International Study of Unruptured Intracranial 
Aneurysms) classification (63), 4 (20%) aneurysms were characterized as small (< 7 
mm), 11 (55%) medium (7-12 mm), 4 (20%) large (13-24mm) and 1 (5%) giant 
aneurysm (>25 mm), with a mean size of 11,2 mm (range 4-26mm).  
Four aneurysms (20%) were ruptured with SAH, whereas 15 (75%) of them were 
incidental and one (5%) presented with compression symptoms. 
Before all procedures, patients underwent complete 4-vessel digital angiography and 
3-dimensional angiography in selected cases. Immediate postprocedure angiographic 
studies were performed to determine successful coil occlusion of the aneurysm as 
well as patency of the parent vessel. 
 
Therapeutic strategy and endovascular procedure 
All therapeutic procedures were conducted under general anesthesia and systemic 
heparinization. To evaluate morphological features of the aneurysm and parent vessel 
and to establish the optimal visual working projections for coil occlusion of the 
aneurysm a cerebral angiography was performed.  
The stent-assisted coil delivery procedure consisted of the placement of the stent in 
the parent artery across the aneurysm neck. A microcatheter was then navigated 
through the stent interstices into the aneurysm sac, and coil embolization was 
performed. In a modified stent delivery procedure, the microcatheter was inserted into 
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the aneurysm sac first and then the stent was placed across the wide neck of the 
lesion. This “jails” the microcatheter in the aneurysm, helping to stabilize the 
microcatheter during delivery of the coils. 
The stenting strategy varied as it follows:  
-Stenting before coiling in 17 patients (85%). In 16 of these 17 aneurysms, the 
microcatheter was introduced through the interstices of the stent, whereas in the other 
one, the catheter was jailed between the stent and the artery wall. 
-Stenting after microcoil embolization in 2 patients (10%). The stent was deployed 
across the aneurysm-neck immediately after the aneurysm coiling. Primary coiling or 
remodeling technique was first used and then the stent was deployed, aiming to 
reduce the late recanalization rate. 
-Stenting without microcoil embolization in 1 patient (5%). Stent deployment across 
the aneurysm-neck as followed by difficult in intrducing the microcatheter through 
the interstices of the stent. Therefore, the patient was treated with the technique of 
flow-diversion. 
-Emergency stenting in 2 patients (10%). In these patients, presentingwith evidence of 
acute complete in-stent-thrombosis which not resolving after intraarterial 
administration of Reopro, placement of a new stent in-stent was necessary.  
Coiling procedure has already been published in the literature (7). Medical 
premedication (160 mg of ASA and 75 mg of clopidogrel per day) at least 3 days 
before the procedure in all unruptured patients, and a loading dose of 300 mg of 
clopidogrel was administered 2 hours before the procedure in ruptured aneurysms was 
administered. A bolus infusion of heparin (70 IU/kg body weight) was done during 
the procedure, and hourly. The adequacy of systemic anticoagulation was monitored 
by keeping  the activated clotting time 2 to 2.5 times the baseline. Systemic 
heparinization was stopped immediately after the procedure in most cases and 
prolonged for 24 hours in selected cases. Unilateral femoral access was obtained 
through a percutaneous femoral artery puncture, and a 6F guide catheter was inserted 
into the parent vessel. When proper alignment was achieved, the microcatheter was 
gently pulled-back to unsheath the stent while gentle forward tension was maintained 
on the stabilizer to keep it in place. Positioning was confirmed by direct fluoroscopic 
visualization. Once the stent was fully deployed, the microcatheter and introducing 
system were removed. A smaller microcatheter, as Excelsior SL-10 (Boston 
Scientific, Natik MA, USA) or Prowler 14 (Codman e Shurtleff Inc., Raynham, MA, 
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USA), was then introduced through the guiding catheter and, with direct fluoroscopic 
visualization and road mapping, guided through the interstices of the stent and into 
the aneurysm. The coils were then delivered within the aneurysm through the 
microcatheter. 
Immediately after EVT, patients were transferred to the intensive care unit for 
monitoring of blood pressure and neurologic status. Patients were maintained on 
clopidogrel (75 mg/d) for 2 months and ASA (160 mg/d) for 6 months. 
Clinical data were obtained from examinations conducted by stroke neurologists or 
neurosurgeons before and after the procedure. Patients were re-evaluated generally 
within 30 days after the intervention. Long-term clinical evaluations were acquired in 
conjunction with the follow-up imaging.  
The clinical outcome measure used was the modified Ranking Scale. The scale runs 
from 0 to 6, running from perfect health without symptoms to death: 
 
mRS  
0 No symptoms 
1 No significant disability. Able to carry put all usual activities, despite some 
symptoms. 
2 Slight disabilty. Able to look after own affairs without assistance but 
unable to carry out all previus activities. 
3 Moderate disability. Requires some helps but able to walk unassisted. 
4 Moderately severe disability. Unable to attend own bodily needs witout 
assistance, and unable to walk unassisted. 
5 Severe disability. Require constant nursing care and attention, bedridden, 
incontinent. 
6 Dead. 
 
Technical success was defined by correct placement of the stent and successful 
positioning of the coils into the body of the aneurysm without compromising the 
parent vessel. Successful stent placement was defined as stable placement with 
complete coverage across the aneurysm neck and patency of the parent artery. 
Satisfactory coil mass position was defined as the stent maintaining coil position 
within the aneurysm sac with parent artery patency. 
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Patients were evaluated by angiography at the end of the procedure to document 
aneurysm obliteration. Angiographic results were classified as complete occlusion 
(>99%) (no contrast filling the aneurysmal sac), neck remnant (91-99%) (residual 
contrast filling the aneurysmal neck), incomplete occlusion (70-90%) (residual 
contrast filling the aneurysmal body) and partial occlusion (<70%). Angiography 
follow-up was performed in all patients within 6 months after the intervention and 
further follow-up was performed by MRA or DSA with evaluation in-stent stenosis,  
progressive thrombosis, recurrence and need for retreatment. 
A recurrence was defined as any increase in the size of the remnant. The recurrence 
was qualified as major if it was saccular and its size would theoretically permit re-
treatment with coils; minor in the other cases. 
All MR images were obtained on a GE 1.5T scanner (Signa HDxt; GE Healthcare, 
Milwaukee, WI, U.S.A.) with an 8 channel head-coil.  
At first, we obtained a T2wi and a three-dimensional (3D) TOF-MRA with 
parameters as follows: spoiled gradient-echo sequence with TR/TE/FA, 30 msec/2.7 
msec/20°; FOV/Matrix, 240 mm/384 × 224; slice thickness/slice overlap, 1.4 
mm/50%; ASSET factor, 1; and actual bandwidth, 31.25 KHz. 
In selected cases we perform a contrast-enhanced MRA (CE-MRA) with parameters 
as follows: Fast Spoiled gradient-echo sequence with TR/TE/FA, 30 
msec/minimum/45°; FOV/Matrix, 240 mm/352 × 352; slice thickness/slice overlap, 
1.0 mm/50%; ASSET factor, 1.75; and actual bandwidth, 41.67 KHz.  
Contrast medium was gadolinium-chelate in all cases. 
Source data of each imaging set were reconstructed with the maximal intensity 
projection (MIP) and volume rendering (VR) technique. All the image interpretation 
of MRA was performed on a PACS monitor by two board-certified neuroradiologists. 
 
2.2 RESULTS      
 
Procedure 
The correct placement of the stent in the parent vessel across the aneurysm neck was 
obtained in all 22 (100%) case. 
A satisfactory coil mass position was obteined in 19 (95%) of 20 patients; the only  
one case treated without coiling embolization is caused for impossibility to navigated 
through the stent interstices with microcatheter into the aneurysm sac.     
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Angiography immediately after treatment procedure showed complete occlusion in  7 
aneurysms (35%), neck remnant in 11 (55%), incomplete occlusion in 1 (5%) and 
partial occlusion in 1 (5%). 
During the endovascular embolization procedure no rupture of the sac or bleeding 
complication occurred, neither any patients needed to undergo to surgical crossover. 
Procedure-related adverse events occurred in one (5%) patient, treated by brachial 
arterial access: a postprocedural pseudoaneurysm presented, then resolved with glue 
embolization without clinical sequelae.  
Three (15%) patients had neurological complications after procedure; in one patient 
there was a muscolar overtone of the left arm at the end of general anestesia, 
spontaneusly resolved without sequelae in 12 hours. Two patients showed a reduced 
consciousness 6 hours after the treatment. Emergency DSA was performed, 
demostrating evidence of acute complete in-stent thrombosis, which resolved after 
intraarterial administration of Reopro (Eli Lilly and Co., Indianapolis, Ind.) and 
placement of a new stent in-stent. However one of this patients died 20 days after 
procedure for severe vasospasm; in the other one, follow-up MRI showed a midbrain 
ischemic lesion with gait disturbances.  
Overall neurological complication rate is 15%, with only one case (5%) of major 
complication. 
 
Of the 20 patients treated with stent deployment, a follow-up imaging studies was 
available in all 19 surviving patients (95%) at an average of 16.2 months (range, 6 to 
50 months). 
 
Six months follow-up 
The first follow-up DSA, compared with initial angiography, showed no changes in 
14 aneurysms (73.7%), progressive thrombosis in 3 (15.7%), and major recurrence in 
2 (10.5%). The 6 months overall rate of succesful procedure is 89.5%. 
Of the three aneurysms with progressive thrombosis, two initially displayed neck 
remnant and later exhibited spontaneous progression of thrombosis at the follow-up,  
while one underwent to stenting without coil embolization and was then treated with 
principle of flow-diversion; in this patient the follow-up angiography showed 
reduction in opacification of the aneurysmal body.  
The two cases  (10%) with major recurrence were those with stent placement after 
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coiling; in these patients, presenting with ruptured aneurysm, occurred a coil 
stretching with partial occlusion of parent vessels; DSA performed immediately after 
the procedure showed subtotal occlusion (neck remnant) of the aneurysm with 
patency of parent vessel; both patients were re-treated by endovascular coiling with 
complete occlusion of the aneurysms. The follow-up imaging exams did not 
demostrate any recurrence. 
In one (5%) of 20 patients the 6 months-follow-up-angiography showed an 
asintomatic moderate endothelial hyperplasia in the stent; at the further DSA and 
MRA follow-up we observed a spontaneous progressive endothelial hyperplasia 
reduction. 
 
Long term follow-up 
The follow-up imaging study, compared with the first follow-up DSA (6 months after 
treatment), showed no changes in 17 (89.5%) of the 19 surviving patients. The patient 
treated with stenting alone demonstrated further progression of thrombosis  during the 
follow-up.  
One patient at 18-months follow-up MRA showed a minor recurrence; no further 
changes in size of the signal into the aneurysm sac was detected in the further follow-
up MRA. 
   
Clinical Folllow-up 
At 30 days clinical follow-up we did not observe any worsening in the mRS in 18 
(90%) of 20 patients; in one case presented worsening of mRS (mRS 2) for  stent-
related midbrain ischemic lesion; the other case was a patient presenting with SAH, 
who died (mRS 6) 20 days after procedure for severe vasosospasm.  
Long term follow-up neurological examination were available in all of 19 surviving 
patients at an average of 16.2 months (range, 6 to 50 months); there were no changes 
in the mRS in all patients. 
All the surviving patients are alive and we did not observe periprocedural or long-
term intracranial bleeding events or symptomatic stent related stenosis/occlusion 
complications. 
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2.3 DISCUSSION 
 
Since the introduction of GDC for treatment of cerebral aneurysms in 1991, numerous 
reports have been published to show its safety and efficacy, particularly in treating 
saccular aneurysms with small neck size. Unfortunately, for those aneurysms with 
large neck size or unfavorable neck-to-dome ratio, durable aneurysm occlusion has 
been more difficult to reach. For complex neck, large, and giant aneurysms, 
recanalization frequently result from unintentional or deliberate undercoiling of the 
neck region and involve a sequence of events leading to coil compaction, with or 
without true continued growth of the aneurysm. 
After stenting, the increased resistance to high flow into the aneurysm dome due to 
the stent interstices is partly responsible for reduced intraaneurysm flow vortices and 
increased stasis (64). Besides this, the rationale for adjunctive stenting in the 
treatment of wide-necked cerebral aneurysms relies on the reestablishment of laminar 
flow patterns, which actually may heal the aneurysm at its neck (65, 66, 67, 68) and 
induction of more profound hemostasis within the aneurysm, contributing to 
intraaneurysmal thrombosis. The theoretical “vascular reconstruction” concept lies on 
the subintimal incorporation of the stent into the parent vessel wall, reinforcing the 
parent artery at the neck margins and potentially reducing the likelihood of recurrent 
aneurysm growth from the neck region and providing an organized substrate to 
support neointimal growth over the aneurysm neck. 
Stented aneurysms had a low rate of immediate total circulatory exclusion, in our 
series 35%, but showed increased delayed occlusion between immediate control and 
the first follow-up angiogram. The fact that immediate total aneurysm occlusion was 
less frequent in the stented group can be explained by the fact that tight coiling is 
more difficult to obtain when the stent is implanted before coiling, giving less 
maneuverability to the coiling microcatheter and thus resulting in looser aneurysm 
packing. Previous published series have also reported a similar finding with a 
relatively low rate of immediate complete aneurysm occlusion with delayed sac 
thrombosis at follow-up (46, 69, 42). Moreover, the use of dual antiplatelet therapy 
during the procedure in addition to heparin did not favor immediate peri-procedural 
sac thrombosis. 
The classification of angiographic results and the diagnosis of a recurrence are 
subjective evaluations. We have chosen to distinguish “minor” from “major” 
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recurrences. Minor changes from the initial or first follow-up angiogram can be 
detected objectively by a rigorous evaluation, but there might be concerns of 
increasing sensitivity of detection of recurrences at the expense of specificity by 
overcalling lesions that might show stability later on. The clinical significance of a  
nonprogressing residual neck, has not been determined certainly, although it is 
probably not without hemorrhagic risks (70). Major recurrences are more definitely of 
concern. Patients who bled during follow-up were shown to have unstable results, 
with residual aneurysms that had progressed since the previous angiographic study. In 
this series none of the patients had re-bleeding in the follow-up period. 
Larger aneurysms are known to recur more frequently (71) and it’s known that there 
were less recurrences in the stented aneurysm despite that this group usually included 
larger aneurysms with lower packing densities than the aneurysms usually treated 
without stent (71); in our series we had found a complessive recurrence rate of 15%, 
with 2 cases of major recurrence at 6 months angiographic follow-up, and one case of 
minor recurrence at 18 months follow-up MRA. This finding shows that the key 
factor to prevent aneurysm recurrence is, aside from the packing density of the sac, 
better arterial wall reconstruction at the level of the neck. However, the duration of 
follow-up was shorter for stented aneurysms due to the fact that the majority of the 
stents were implanted during the last 3 years, and the duration of follow-up is 
obviously a key factor known to influence angiographic or imaging recurrence rate. 
Longer follow-up is mandatory to draw more definitive conclusions. 
In our series of aneurysms treated with stent or stent-assisted coiling, major 
recurrence was observed in 2 (10%) patients and successful retreatment was 
accomplished in both cases. Recurrences seemed to be more frequent in posterior 
circulation aneurysms (all 3 cases) in agreement with other previous studies (72). This 
may be related to the size and etiology of the aneurysm. 
Experience in cardiology teaches that it might be important to place stented patients 
on dual antiplatelet therapy to prevent thrombotic events. 
There were more procedure-related complications in the stented patients. The 
conjunction of the use of antiplatelet drugs and guidewire exchange maneuvers 
explained overincidence of hemorrhagic complications in stented aneurysms 
compared with coiling aneurysms and more specifically vessel perforations. The 
necessity of dual antiplatelet therapy in stent-assisted coil embolization is known to 
increase the risk of hemorrhagic complications. However in our series we observed no 
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periprocedural bleeding complication and no rebleeding events in the clinical follow-
up; this might be due to the small number of ruptured aneurysms (4 of 20, 20%) 
included in the study. 
Particullary care is necessary for patients presenting with SAH; this subgroup of   
patients with stented aneurysms wasn’t obviously placed on dual antiplatelet therapy. 
The protocol of pretreatment with an antiplatelet regimen for patients with acutely 
ruptured aneurysms is still controversial. Considering the inherent thrombogenicity of 
stent placement and risk of severe rebleeding after antiplatelet therapy, we 
administered antiplatelet drugs very shortly before stent placement, as advocated by  
some authors (65, 46); in our Institution we administrated 500 mg of ASA and 300-
600 mg of clopidogrel by nasogastric tube immediately after procedure. Nevertheless, 
none of the cases had post-procedural bleeding or re-bleeding during the follow-up 
period. However, Katsaridis et al. (72), reported that stent-assisted coiling without any 
pretreatment is safe in ruptured and unruptured aneurysms on the basis of experience 
in 54 cases. Therefore, further study is required to evaluate the benefit-risk balance 
for different protocols. 
The only one case of procedure-related adverse event was a brachial-artery 
pseudoaneurysm occurred in a patients presenting with SAH; this might have been 
favored by antiplatelet theraphy. 
Thromboembolic complications could be more frequent in the stented patients; this 
finding was similar in a previously reported series (73). 
However, dual antiplatelet drug administration before stent delivery had later 
diminished the occurrence of such complications.  
We observed that both cases of stent thrombosis were patients presenting with SAH  
due to rupture of aneurysms of the posterior circulation and occurred within 6 hours 
after endovascular treatment; both cases required the intra-arterial use of abciximab 
(ReoPro) and subsequent placement of a new stent. 
In our series permanent neurological deficits occurred in only one (5%) of stented 
patients, which is a similar rate compared with previously published series (65, 74, 
46). 
The incidence of in-stent stenosis is likely related to neointimal growth as has been 
previously suggested (75), which might be secondary to endothelial injury. Due to 
shear stress of the stent deployment, new endothelial growth called “neointima” 
occurs. The content of neointima changes over time. The early neointima contains a 
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large quantity of proteoglycans, which provide both the volume of the neointima due 
to high water content, and facilitate cell migration and proliferation. However, as the 
neointima ages, it loses the bulky, hydrated proteoglycans, which results in reduction 
in the neointimal volume and the stimulus for smooth muscle cell proliferation. 
Meanwhile, the collagen matures, transforming from the fibrillar type to the cross 
linked type and the smooth muscle cells also change their phenotype from synthetic to 
contractile cells, with the cell content remaining relatively stable. As a result, 
neointimal regression may occur after 6 months. Late angiographic improvement has 
been proposed to be probably due to fibrotic maturation of in-stent neointima (75).  
Unlike coronary balloon-mounted stents, self-expanding intracranial stents such as the 
Enterprise (Cordis Neurovascular J&J, Miami Lakes, Fla) or the Neuroform (Stryker, 
Kalamazoo, MI, USA) have low radial force and are less traumatic. In our series, one 
patient (5%) with angiographic follow-up presented with an asymptomatic in-stent 
stenosis of 30% with the newer self-expanding stent designed for the neurovascular 
realm. 
Great care is necessary to preserve perforators at the time of stent placement,  because 
important perforators, that exit from the stented arterial segment during aneurysm 
embolization, may be occluded. As discussed in the coronary literature (76) future 
development of absorbable stents should be considered to prevent permanent jailing 
of important perforators.  
The correct imaging follow-up protocol for the patients treated with intracranial stent 
remains unclear. Transfemoral cerebral arteriography has been considered as the 
method of reference for evaluation of the stented arteries and for detection of 
endothelial hyperplasia. However, it is invasive and could have the potential risk of 
neurological complications (77). Contrast-enhanced MR angiography (CE-MRA) 
seemed to be alternative to the arteriography in terms of detecting restenosis of 
stented large arteries such as carotid, iliac or femoral arteries (78, 79). However, CE-
MRA requires the use of gadolinium contrast media, which presents the risk of 
anaphylaxis, renal complication, and nephrogenic systemic fibrosis (80). 
Time-of-flight (TOF) MRA is a widely used and well-established MRA technique for 
evaluating intra- and extra-cranial arterial pathology without contrast media (81, 82). 
However, various metallic stents cause the variable degree of luminal signal loss of 
the stented artery due to susceptibility artifact or radiofrequency (RF) shielding 
artifact (82, 83). TOF-MRA can demonstrate pathology of the intracranial large 
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arteries that is less than 3 mm in diameter. However, it is difficult to interpret patency 
and/or degree of stenosis of stented artery on TOF-MRA because of susceptibility 
artifact or RF shielding effect of intracranial stents (84, 85). It is known that wider 
BW can reduce susceptibility artifact and overcome RF shielding effect. However, 
this might reduce signal to noise ratio of the TOF-MRA (86). 
At our Institution, we decided to perform a DSA within 6 months in all patients to 
detect the presence of recurrence and endothelial hyperplasia; it is known that the 
intra-stent endothelial hyperplasia has its highest expression after 6 months and then 
tends to decrease, as previously discussed (75). If the patient shows endothelial 
hyperplasia is always followed with angiographic follow-up. If at 6 months- 
angiography there are no signs of endothelial hyperplasia, the patient is monitored 
with 3D TOF-MRA, and CE-MRA in selected cases; if there are no signs of 
recurrence it continue the follow-up to 18 months and then every 3 years. If it’s 
detected a minor recurrence, the patient is monitored with annual MRA (3D TOF and 
CEMRA); in case of major recurrence a DSA is performed, also in anticipation of a 
possible re-treatment. 
 
2.4 CONCLUSION 
 
The use of the stent for intrcranial aneurysms treatment integrates 3 principles:  
-“endovascular bypass” with anatomic reconstruction of the diseased parent vessel;  
-mechanical support for coil embolization; 
-flow diversion.  
Our findings suggest that the endovascular treatment of intracranial aneurysms using 
the stent is feasible, effective and safe. In addition, the use of stent allows to expand 
the pool of patients who benefits of endovascular treatment. The follow-up proved 
intact parent arteries and stable occlusion rates in the majority of treated aneurysms. 
Nevertheless, long-term data on safety and efficacy and larger groups of patients are 
necessary, as well as a universally shared follow-up protocol. 
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PICTURE 1 
a) and b) left internal carotid artery angiography showed carotid-ophtalmic wide-neck 
aneurysm. 
c) Volume rendering of 3D rotational angiography allowed us to choose the best 
work-projection.  
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d) MIP reconstruction of 3D rotational angiography allowed us to misure body and 
neck of the aneurysm. 
e) Roadmap picture: a small microcatheter positioned into the parent artery. 
f) Roadmap picture: the stent positioned across the aneurysm neck.  
g) and h) left internal carotid artery angiography showed correct stent placement with 
preserved patency of parent artery. 
i) Roadmap picture: a guidewire passed through the interstices of the stent 
l) Roadmap picture: a small microcatheter passed through the interstices of the stent 
into the aneurysm body. 
m) Partial coiling of the aneurysm body. 
n) Cast of coils kept inside the body of the aneurysm by the stent. 
o) and p) left internal carotid artery angiography showed complete occlusion of the 
wide-neck aneurysm. 
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PICTURE 2 
a) left vertebral artery angiography showed basilar artery-apex wide-neck aneurysm. 
b) left vertebral artery angiography showed complete occlusion of the wide-neck 
aneurysm. 
c) and d) 6-months left vertebral artery angiography showed no recurrence. 
e) 18-months axial 3D Time-Of-Flight MRA showed no flow signal into the treated 
aneurysm. 
f) Volume Rendering reconstruction of the 3D Time-Of-Flight MRA confirmed the 
absence of the flow signal into the aneurysm; note the signal loss into basilar-artery 
stent. 
 
